1. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Issue 1 (January 2020) Authors: Mateo, Joaquin; Porta, Nuria; Bianchini, Diletta; McGovern, Ursula; Elliott, Tony; Jones, Robert; Syndikus, Isabel; Ralph, Christy; Jain, Suneil; Varughese, Mohini; Parikh, Omi; Crabb, Simon; Robinson, Angus; McLaren, Duncan; Birtle, Alison; Tanguay, Jacob; Miranda, Susana; Figueiredo, Ines; Seed... Journal: Lancet oncology Issue: Volume 21:Issue 1(2020) Page Start: 162 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors. Issue 6 (18th June 2022) Authors: Papadatos-Pastos, Dionysis; Yuan, Wei; Pal, Abhijit; Crespo, Mateus; Ferreira, Ana; Gurel, Bora; Prout, Toby; Ameratunga, Malaka; Chénard-Poirier, Maxime; Curcean, Andra; Bertan, Claudia; Baker, Chloe; Miranda, Susana; Masrour, Nahal; Chen, Wentin; Pereira, Rita; Figueiredo, Ines; Morilla, Ricard... Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 6(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗